The sustained cardiopulmonary benefits strengthen the clinical and regulatory case for z-rostudirsen, potentially de-risking the path to FDA accelerated approval. Traders should monitor for upcoming interactions with the FDA and potential BLA submission timelines.
Price Chart
Executive Summary
Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in heart and lung function for DMD patients treated with z-rostudirsen, a therapy targeting exon 51 skipping. The results, presented at the 2026 MDA Conference, suggest potential clinical benefits beyond muscle function, including cardiopulmonary improvements compared to natural history decline.
Key Facts
- 24-month data from the DELIVER trial show improvement in lung function (FVC%p), circumferential strain, and left ventricular ejection fraction vs. expected decline in natural history.
- Z-rostudirsen demonstrated a favorable safety profile with mostly mild or moderate TEAEs; no related serious adverse events in the registrational cohort.
- Therapy has FDA Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for DMD amenable to exon 51 skipping.
- Most participants at 24 months were on lower doses than the registrational 20 mg/kg, suggesting potential for even greater efficacy at full dose.
- Data presented at a late-breaking session at the 2026 MDA Clinical & Scientific Conference.
Financial Impact
Potential path to accelerated approval; increases likelihood of future revenue and partnership interest
Risk Factors
- Long-term efficacy may not reflect full potential, as most patients were not continuously on the 20 mg/kg registrational dose.
- Forward-looking statements carry inherent risk; final trial results or regulatory decisions may differ.
- No Phase 3 data yet; approval remains contingent on confirmatory trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251476 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.39 (+41.15%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.39 (−41.15%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.39 (+40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.39 (−40.12%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.39 (−40.19%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.39 (+33.69%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.39 (−34.37%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.39 (−29.37%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.39 (+30.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access